By Denny Jacob
Invo BioScience shares surged 43% to 24 cents following quarterly revenue that more than doubled from a year earlier.
The stock, which is down about 44% on the year, is on pace for its largest percentage increase since 2021 when it rose more than 202%.
The fertility company posted $348,025 in revenue for the first quarter ended March 31, a 114% increase from $162,598 in the year-ago period.
Loss narrowed slightly to $2.55 million, or 20 cents a share, from a loss of $2.77 million, or 23 cents a share, a year earlier.
“We are extremely pleased to see the existing clinics nearing break-even and look forward to each of them generating positive cashflows and profits in the near future,” said Chief Executive Steve Shum, referring to the company’s centers.
Write to Denny Jacob at [email protected]
Read the full article here
